GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Corona Remedies Ltd

Corona Remedies Reports Q2 FY27 Revenue at ₹ 441.2 Cr, up 22.2% YoY

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 30 Oct 2026, 06:46 PM IST  ·  BSE ID: 6058fdad-bfdb-4a55-98f9-649e57e09606
View Original BSE Filing (PDF)
💡
In Simple Terms
Corona Remedies saw its sales grow by 22.2% to ₹ 441.2 Cr in the latest quarter, with profits also increasing.
🤖 AI Summary
  • Corona Remedies' Revenue from Operations for Q2 FY27 was ₹ 441.2 Cr, representing a 22.2% YoY increase.
  • Profit After Tax for Q2 FY27 reached ₹ 60.3 Cr, a 15.3% increase compared to Q2 FY26.
  • Half-year Revenue for H1 FY27 amounted to ₹ 863.6 Cr, up 22.0% from H1 FY26.
  • Company received ANVISA GMP Certification for its manufacturing facility at Bhayla, Ahmedabad.
  • Chronic + Semi Chronic business contributed 71.2% to Q2 FY27 revenue, up from 67.7% in Q2 FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
441.2 ₹ in Cr
22.2%
EBITDA (Q2 FY27)
96.0 ₹ in Cr
22.3%
Profit After Tax (Q2 FY27)
60.3 ₹ in Cr
15.3%
Revenue from Operations (H1 FY27)
863.6 ₹ in Cr
22.0%
EBITDA (H1 FY27)
189.1 ₹ in Cr
27.5%
Profit After Tax (H1 FY27)
120.4 ₹ in Cr
22.2%
🏢 How This Affects the Company
📈
Business Impact
The company recorded its highest ever Revenue from Operations, indicating continued market penetration and growth in its pharmaceutical segments, outpacing the Indian Pharmaceutical Market (IPM). The ANVISA GMP certification expands its export potential to Brazil and other regulated markets.
💰
Financial Impact
Revenue growth of 22.2% year-on-year for Q2 FY27 and 22.0% for H1 FY27 directly impacts the top-line. PAT Margin for Q2 FY27 was 13.7%, lower than 14.5% in Q2 FY26 due to higher depreciation and amortization from new facilities and brand acquisitions.
⚙️
Operational Impact
The ANVISA GMP certification confirms the quality standards of its Bhayla manufacturing facility for Oral Solid Dosage and Women’s Hormone production lines, enhancing manufacturing excellence and export capabilities.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results press release.
👤
Who Is Affected
All shareholders are affected as the company's Q2 FY27 financial performance and operational milestones influence the company's fundamental value and future prospects.
🔍
Management Signal
Management prioritizes strong revenue growth, outperforming the IPM, and investing in new facilities and brand acquisitions for future expansion.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results – observe revenue and profit after tax trends.
Updates on revenue contribution from newly commissioned facilities and acquired brands.
Details on new product introductions and chronic portfolio growth.
LOW RISK The filing reports positive financial results and an operational certification without highlighting new specific risks.
💡 Investor Takeaway
Corona Remedies reported Q2 FY27 Revenue from Operations at ₹ 441.2 Cr, up 22.2% YoY, and H1 FY27 Revenue at ₹ 863.6 Cr, up 22.0% YoY. PAT for Q2 FY27 was ₹ 60.3 Cr, increasing 15.3% YoY. The company also secured ANVISA GMP Certification.
⚖️ Strengths & Concerns

✅ Positives

  • Revenue from Operations for Q2 FY27 increased 22.2% year-on-year to ₹ 441.2 Cr, demonstrating strong top-line growth.
  • Company received ANVISA GMP Certification for its Bhayla facility, enhancing global market access and quality recognition.

⚠️ Concerns

  • PAT Margin for Q2 FY27 decreased to 13.7% from 14.5% in Q2 FY26, due to higher depreciation and amortization charges.
  • Profit After Tax growth of 15.3% for Q2 FY27 was slower than the 22.2% revenue growth for the same period.
📅 Company Track Record
Corona Remedies consistently reported revenue growth in prior quarters, with Q1 FY27 revenue up 21.9% to ₹ 422.4 Cr and PAT up 30.1%. This Q2 FY27 filing continues that trend with strong double-digit growth in both revenue and profit after tax, further building on its established financial performance.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Corona Remedies' Revenue from Operations for Q2 FY27?
Corona Remedies reported Revenue from Operations of ₹ 441.2 Cr for the second quarter ended September 30, 2026, marking a 22.2% increase from Q2 FY26.
What was Corona Remedies' Profit After Tax for Q2 FY27?
The Profit After Tax for Corona Remedies in Q2 FY27 was ₹ 60.3 Cr, which is a 15.3% increase compared to ₹ 52.3 Cr in Q2 FY26.
What is the EBITDA Margin for Corona Remedies in Q2 FY27?
Corona Remedies' EBITDA Margin for Q2 FY27 was 21.7%, which is the same as the 21.7% reported in Q2 FY26.
What significant certification did Corona Remedies receive?
Corona Remedies received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its Bhayla, Ahmedabad manufacturing facility.
How did Corona Remedies' half-year revenue perform in H1 FY27?
For the half year ended September 30, 2026, Corona Remedies reported Revenue from Operations of ₹ 863.6 Cr, representing a 22.0% increase from H1 FY26.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.